The COVID-19 Clinical Landscape and Its Impact on Clinical Research and the Biopharmaceutical Sector


About the white paper

Update & Revised 23 Jul 2020

The COVID-19 pandemic has dramatically disrupted the global community and economy. While new development programs for COVID-19 spring up globally, the clinical research paradigm for study execution is being changed, and our industry is being forced to adapt and find new creative ways to further clinical research in all areas, not just for COVID-19. 

In this white paper, we partnered with Informa Pharma Intelligence to bring you the latest information on this pandemic.  On July 23, 2020, we updated this white paper to reflect current data. The white paper includes:

  • Status of COVID-19 pandemic – the global spread
  • Our industry’s response to combat COVID-19 and new projects underway
  • The pandemic’s impact on ongoing “traditional” research
  • How CROs and Sponsors are adapting to trial conduct in the new environment
  • The Human Element – Considering Patient Enrollment


Complete the form to get the white paper!